Table 1 Clinical characteristics of HRR Cohort (n = 240)
|  | Pt-resistant (N = 42) | Pt-sensitive (N = 198) | Total (N = 240) | p-value |
|---|---|---|---|---|
Age | 0.928 | |||
 Median (SD) | 54 (8.4) | 53 (8.8) | 53 (8.7) |  |
 Range | 37.0—69.0 | 36.0- 83.0 | 36.0—83.0 |  |
FIGO stage | 0.038 | |||
 II | 0 (0%) | 14 (7.1%) | 14 (5.8%) |  |
 III | 30 (71.4%) | 154 (77.8%) | 184 (76.7%) |  |
 IV | 12 (28.6%) | 30 (15.2%) | 42 (17.5%) |  |
Residual tumor | 0.013 | |||
 non-R0 | 30 (71.4%) | 100 (50.5%) | 130 (54.2%) |  |
 R0 | 12 (28.6%) | 98 (49.5%) | 110 (45.8%) |  |
CA125 | 0.021 | |||
 < 500 U/ml | 7 (16.7%) | 69 (34.8%) | 76 (31.7%) |  |
 ≥ 500 U/ml | 35 (83.3%) | 129 (65.2%) | 164 (68.3%) |  |
HE4 | 0.008 | |||
 < 400 pmol/L | 12 (28.6%) | 100 (51.0%) | 112 (47.1%) |  |
 ≥ 400 pmol/L | 30 (71.4%) | 96 (49.0%) | 126 (52.9%) |  |
 N-Miss | 0 | 2 | 2 |  |
tBRCA | 0.003 | |||
 WT | 37 (88.1%) | 128 (64.6%) | 165 (68.8%) |  |
 Mut | 5 (11.9%) | 70 (35.4%) | 75 (31.2%) |  |
non-BRCA HRR | 0.170 | |||
 WT | 35 (83.3%) | 145 (73.2%) | 180 (75.0%) |  |
 Mut | 7 (16.7%) | 53 (26.8%) | 60 (25.0%) |  |